What is Sarepta Therapeutics?
Sarepta Therapeutics is a precision genetic medicine company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Precision genetic medicine
- Headquarters
- Cambridge, MA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: SRPT
What is Sarepta Therapeutics?
Sarepta Therapeutics is a precision genetic medicine company headquartered in Cambridge, MA.
Sarepta Therapeutics operates in precision genetic medicine and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around DMD therapies, Gene therapy, RNA technologies, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Sarepta Therapeutics is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: SRPT, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Sarepta Therapeutics offer?
Sarepta Therapeutics's profile centers on DMD therapies, Gene therapy, RNA technologies, ELEVIDYS.
- DMD therapies· Precision genetic medicine
- Gene therapy· Precision genetic medicine
- RNA technologies· Precision genetic medicine
- ELEVIDYS· Precision genetic medicine
- Exon-skipping therapies· Precision genetic medicine
- Rare disease pipeline· Precision genetic medicine
How does Sarepta Therapeutics make money?
Sarepta Therapeutics makes money through commercial activity tied to precision genetic medicine.
Sarepta Therapeutics monetizes through the commercial model common to precision genetic medicine: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Sarepta Therapeutics?
Sarepta Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- Sarepta Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Sarepta Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Sarepta Therapeutics technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Sarepta Therapeutics's leadership?
Sarepta Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.sarepta.com- Sarepta Therapeutics investor relationsInvestor relations / corporate contactcontact via https://www.sarepta.com
- Sarepta Therapeutics sales or partnershipsCommercial contact routecontact via https://www.sarepta.com
- Sarepta Therapeutics media relationsMedia or communications contact routecontact via https://www.sarepta.com
How is Sarepta Therapeutics funded?
Sarepta Therapeutics's current status is Public company; Nasdaq: SRPT.
Sarepta Therapeutics's current capital profile is best understood through its current status: Public company; Nasdaq: SRPT. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Sarepta Therapeutics get here?
Sarepta Therapeutics's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingSarepta Therapeutics is foundedThe company begins building in precision genetic medicine.
- Scale-upCommercial footprint expandsSarepta Therapeutics broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: SRPTOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Sarepta Therapeutics's competitors?
Sarepta Therapeutics competes with larger platform incumbents and focused specialists in precision genetic medicine.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Sarepta Therapeutics — frequently asked questions
